$6.69 +0.30 (%) AcelRx Pharmaceuticals Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO

    Benzinga | Dec. 16, 2014 | 17:05PM EST
  2. Mid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike Higher

    Benzinga | Nov. 11, 2014 | 15:17PM EST
  3. Mid-Morning Market Update: Markets Edge Lower; D.R. Horton Posts Downbeat Profit

    Benzinga | Nov. 11, 2014 | 10:35AM EST
  4. AcelRx Pharmaceuticals Receives International Standards Organization Certification Of Its Quality Management System

    Benzinga | Nov. 10, 2014 | 07:09AM EST
  5. AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting

    Benzinga | Oct. 27, 2014 | 07:40AM EST
  6. Nike Jumps On Strong Results; Powell Industries Shares Slide

    Benzinga | Sep. 26, 2014 | 13:04PM EST
  7. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 26, 2014 | 10:07AM EST
  8. Morning Market Losers

    Benzinga | Sep. 26, 2014 | 09:45AM EST
  9. Benzinga's Top #PreMarket Losers

    Benzinga | Sep. 26, 2014 | 08:08AM EST
  10. AcelRx falls on FDA rejection

    IBD | Jul. 28, 2014 | 18:49PM EST
  11. AcelRx Pharma Plunges After FDA Rejects Device

    IBD | Jul. 28, 2014 | 14:35PM EST
  12. Morning Market Losers

    Benzinga | Jul. 28, 2014 | 09:48AM EST
  13. AcelRX Selling Off Sharply On FDA Reexamination

    Benzinga | Jul. 28, 2014 | 09:15AM EST
  14. Benzinga's Top Downgrades

    Benzinga | Jul. 28, 2014 | 08:58AM EST
  15. Benzinga's Top #PreMarket Losers

    Benzinga | Jul. 28, 2014 | 08:19AM EST
  16. Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold

    Benzinga | Jul. 28, 2014 | 07:33AM EST
  17. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 25, 2014 | 08:13AM EST
  18. US Stock Futures Down In Pre-Market Trade

    Benzinga | Jul. 7, 2014 | 07:34AM EST
  19. Top Funds Like Facebook And Health Care Stocks

    IBD | Jan. 7, 2014 | 18:59PM EST
  20. AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO

    Benzinga | Dec. 16, 2013 | 07:52AM EST
  21. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data

    Benzinga | Dec. 13, 2013 | 07:33AM EST
  22. AcelRx Announces Zalviso NDA Accepted for Filing by FDA

    Benzinga | Dec. 2, 2013 | 07:34AM EST
  23. AcelRx Pharma Issues NDA for Zalviso, Submission Required Payment of $1.95M to FDA

    Benzinga | Sep. 30, 2013 | 07:35AM EST
  24. UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals on Numerous Potential Catalysts Ahead

    Benzinga | Aug. 13, 2013 | 08:41AM EST
  25. AcelRx Pharma Announces Exercise of Option to Buy Additional Shares

    Benzinga | Dec. 14, 2012 | 05:16AM EST
  26. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 7, 2012 | 01:10AM EST
  27. AcelRx Pharmaceuticals Prices 12.5M Share Offering at $3.31/Share

    Benzinga | Dec. 6, 2012 | 23:33PM EST
  28. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 5, 2012 | 00:09AM EST
  29. FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain

    Benzinga | Nov. 15, 2012 | 01:28AM EST
  30. AcelRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System Meets Primary End-Point

    Benzinga | Nov. 14, 2012 | 15:24PM EST
  31. AcelRx Pharmaceuticals Doses the First Subjects in ARX-04 Phase 2 Study

    Benzinga | Nov. 5, 2012 | 00:39AM EST
  32. AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab PCA System

    Benzinga | Oct. 3, 2012 | 01:41AM EST
  33. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

    Benzinga | Aug. 29, 2012 | 01:32AM EST
  34. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms

    Benzinga | Jun. 20, 2012 | 01:30AM EST
  35. AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain

    Benzinga | Mar. 7, 2012 | 00:23AM EST
  36. Morning Market Losers

    Benzinga | Dec. 30, 2011 | 03:24AM EST
Trading Center